Sort   by:  
 Page size 
UnknownEfficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.
Not available
S-EPMC5791828 | biostudies-literature
UnknownTalimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.
Not available
S-EPMC8011715 | biostudies-literature
UnknownPatient Experiences with Avelumab in Treatment-Naive Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial.
Not available
S-EPMC7340640 | biostudies-literature
UnknownOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Not available
S-EPMC5706778 | biostudies-literature
UnknownIdentification of an Immature Subset of PMN-MDSC Correlated to Response to Checkpoint Inhibitor Therapy in Patients with Metastatic Melanoma.
Not available
S-EPMC8002694 | biostudies-literature
UnknownEfficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.
Not available
S-EPMC5885245 | biostudies-literature
UnknownEfficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.
Not available
S-EPMC4269803 | biostudies-literature
UnknownClinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.
Not available
S-EPMC5483259 | biostudies-literature
UnknownSafety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature.
Not available
S-EPMC5687540 | biostudies-literature
UnknownProlonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
Not available
S-EPMC5648545 | biostudies-literature
Sort   by:  
 Page size